Home | Contact us | Disclaimer
As an emerging biotechnology company, Transition is forging collaborations and licensing agreements with other biotech and pharmaceutical companies as an important part of its drug-development strategy.

Transition is open to discuss any licensing/collaboration opportunities for our products, as well as potential partnerships that may be of mutual interest. Please contact:

Contact information

Mr. Carl Damiani
President and Chief Operating Officer
T. 416.260.7770 ext. 206
© 2015 Transition Therapeutics Inc.